Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Parsaclisib - Incyte Corporation

Next Previous
X
Search
Drug Profile

Parsaclisib - Incyte Corporation

Alternative Names: IBI-376; INCB-050465; INCB-50465

Latest Information Update: 28 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Incyte Corporation; Innovent Biologics; Mayo Clinic; National Cancer Institute (USA)
  • Class Antianaemics; Antihaemorrhagics; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Ketones; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Autoimmune haemolytic anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Follicular lymphoma
  • Phase III Myelofibrosis
  • Phase II B-cell lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
  • Phase I/II Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Solid tumours
  • No development reported Systemic lupus erythematosus
  • Discontinued Autoimmune haemolytic anaemia; Sjogren's syndrome

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in B-cell lymphoma(Second-line therapy or greater) in Japan (PO, Tablet)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Combination therapy, First-line therapy, Newly diagnosed) in USA (PO)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Combination therapy, Second-line therapy or greater) in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top